<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04399538</url>
  </required_header>
  <id_info>
    <org_study_id>C3711005</org_study_id>
    <nct_id>NCT04399538</nct_id>
  </id_info>
  <brief_title>Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis</brief_title>
  <official_title>PHASE 2A, 2-PART, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY PLACEBO-CONTROLLED, PARALLEL-GROUP (SPONSOR OPEN) STUDY TO ASSESS PHARMACODYNAMICS AND SAFETY OF PF-06865571 (DGAT2I) COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH PRESUMED NONALCOHOLIC STEATOHEPATITIS (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effect of coadministration of a range of doses of DGAT2i with 1
      dose of ACCi, on hepatic steatosis and the ability of DGAT2i to mitigate ACCi-induced
      elevations in serum triglycerides. The study has a 2-part design with sequential conduct of
      Part 1 and Part 2 with each part conducted in distinct/separate cohorts of participants. The
      overall study design, objectives/endpoints, eligibility criteria for both parts is envisioned
      to be identical, however, data from Part 1 will be used to determine whether to conduct Part
      2.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">November 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 23, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Dose-ranging of combination doses</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind, Double-dummy, Placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in liver fat</measure>
    <time_frame>Week 6</time_frame>
    <description>Percent change in liver fat as assessed via magnetic resonance imaging using proton density fat fraction acquisition (MRI-PDFF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in fasting serum triglyceride levels</measure>
    <time_frame>Day 1 to Week 6</time_frame>
    <description>Percent change from baseline in fasting serum triglyceride levels over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with treatment emergent adverse events</measure>
    <time_frame>Day 1 to Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with clinically significant, abnormal ECGs</measure>
    <time_frame>Day 1 to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with clinically significant, abnormal vital signs</measure>
    <time_frame>Day 1 to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with clinically significant, abnormal laboratory values</measure>
    <time_frame>Day 1 to Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive medication for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DGAT2i (25 mg BID) + ACCi (10 mg BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive medication for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DGAT2i (100 mg BID) + ACCi (10 mg BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive medication for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DGAT2i (300 mg QD) + ACCi (20 mg QD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive medication for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DGAT2i (300 mg BID) + ACCi (10 mg BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive medication for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06865571</intervention_name>
    <description>Tablet</description>
    <arm_group_label>DGAT2i (100 mg BID) + ACCi (10 mg BID)</arm_group_label>
    <arm_group_label>DGAT2i (25 mg BID) + ACCi (10 mg BID)</arm_group_label>
    <arm_group_label>DGAT2i (300 mg BID) + ACCi (10 mg BID)</arm_group_label>
    <arm_group_label>DGAT2i (300 mg QD) + ACCi (20 mg QD)</arm_group_label>
    <other_name>DGAT2i</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05221304</intervention_name>
    <description>Tablet</description>
    <arm_group_label>DGAT2i (100 mg BID) + ACCi (10 mg BID)</arm_group_label>
    <arm_group_label>DGAT2i (25 mg BID) + ACCi (10 mg BID)</arm_group_label>
    <arm_group_label>DGAT2i (300 mg BID) + ACCi (10 mg BID)</arm_group_label>
    <arm_group_label>DGAT2i (300 mg QD) + ACCi (20 mg QD)</arm_group_label>
    <other_name>ACCi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI ≥25 and ≤ 40 kg/m2

          -  concomitant medical conditions associated with NAFLD

        Exclusion Criteria:

          -  Evidence of other causes of liver disease such as Alcoholic steatohepatitis,
             (de)compensated cirrhosis, active viral hepatitis

          -  Any condition possibly affecting drug absorption

          -  Unstable liver function tests

          -  Recent cardiovascular event(s),

          -  Malignancies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3711005</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

